{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-245102","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2025-10-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.051984+00:00","generated_at":"2026-05-17T03:02:31.448658+00:00","sec_items":["2.02","2.05","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Alector's Phase 3 latozinemab trial fails; workforce cut 49%, R&D head resigns","bullets":["Phase 3 INFRONT-3 trial of latozinemab in FTD-GRN missed clinical co-primary endpoint; biomarker endpoint met but no treatment effects seen.","Workforce reduction of ~49% (about 75 employees); restructuring charges ~$7.7M; completion expected by H1 2026.","President and Head of R&D Sara Kenkare-Mitra resigns effective Dec 22, 2025; separation includes 9 months salary and 50% bonus.","Preliminary cash, equivalents, and short-term investments ~$291.1M as of Sep 30, 2025; runway expected through 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-245102","json":"https://secwatch.observer/filing/0001193125-25-245102.json","markdown":"https://secwatch.observer/filing/0001193125-25-245102.md","text":"https://secwatch.observer/filing/0001193125-25-245102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000119312525245102/0001193125-25-245102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000119312525245102/alec-20251020.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:02:31.448658+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"395394f6f6e054955941a8a9d50641c9517387b2","claim":"Alector, Inc. announced a restructuring with charges of approximately $7.7 million affecting across the organization (approximately 75 employees).","evidence_excerpt":"The Company initiated a reduction in force impacting approximately 75 employees across the organization. Total incremental restructuring charges associated with the reduction in force are expected to be approximately $7.7 million.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1653087/000119312525245102/0001193125-25-245102-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $7.7 million"},{"label":"Affected area","value":"across the organization"},{"label":"Headcount","value":"approximately 75 employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}